As of May 2022 Adaptimmune Therapeutics has a market cap of $0.26 Billion. This makes Adaptimmune Therapeutics the world's 5404th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to mesure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2022 | $0.26 B | -54.68% |
2021 | $0.58 B | -29.79% |
2020 | $0.83 B | 561.11% |
2019 | $0.12 B | -79.01% |
2018 | $0.60 B | -3.92% |
2017 | $0.62 B | 118.3% |
2016 | $0.28 B | -66.42% |
2015 | $0.85 B |
On May 21st, 2022 the market cap of Adaptimmune Therapeutics was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
![]() uniQure QURE | $0.64 B | 141.09% | ๐ณ๐ฑ Netherlands |
![]() Novavax NVAX | $4.17 B | 1,472.35% | ๐บ๐ธ USA |
![]() Exelixis EXEL | $5.69 B | 2,045.86% | ๐บ๐ธ USA |
![]() Enzo Biochem ENZ | $0.11 B | -56.33% | ๐บ๐ธ USA |